TABLE 4.
Summary of the pharmacokinetic parameters of zanubrutinib administered alone and with omeprazole 20 mg
| Parameter | Zanubrutinib 160 mg b.i.d. only (Day 13) (n = 17) | Probe drugs + zanubrutinib 160 mg b.i.d. (Day 18) (n = 17) |
|---|---|---|
| AUC0‐t (h*ng/mL) | 1032 (34.49) | 1073 (33.75) |
| AUC0‐τ (h*ng/mL)a | 1048 (35.18) | 1076 (33.69) |
| Cmax (ng/mL) | 231 (48.6) | 233 (40.4) |
| Tmax (h)b | 2.00 (1.00–4.00) | 2.00 (1.00–3.00) |
| t1/2 (h)c | 2.70 (0.851) | 2.93 (1.17) |
Abbreviations: AUC0‐t = area under the concentration–time curve from time zero to the time of the last quantifiable concentration; AUC0‐τ = area under the concentration–time curve over a dosing interval τ (where τ = 12 h); b.i.d. = twice daily; C max = maximum observed plasma concentration; CV = coefficient of variation; t 1/2 = apparent terminal elimination half‐life; T max = time of the maximum observed plasma concentration.
Note: Geometric mean (CV%) data are presented;
a
n = 16;
b
Median (min‐max) are provided for T max;
c
Arithmetic mean (SD) data are provided for t 1/2